apple tree life sciences, inc.

111 eighth avenue
new york, new york 10011

NYS Entity Status
ACTIVE

NYS Filing Date
JANUARY 08, 2013

NYS DOS ID#
4342734

County
NEW YORK

Jurisdiction
DELAWARE

Registered Agent
CT CORPORATION SYSTEM
111 EIGHTH AVENUE
NEW YORK, NEW YORK, 10011

NYS Entity Type
FOREIGN BUSINESS CORPORATION

Name History
2013 - APPLE TREE LIFE SCIENCES, INC.









Buffer

submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Near The East River, Plans Emerge For NY’s Next Life Science Center
    By Ben Fidler - Monday Aug 21, 2017

    At a time when biotech incubators and shared spaces are beginning to multiply in Manhattan, work on what could rank among the city’s largest biotech centers—if it can all come together—is just getting underway. According to Paul Wexler, a longtime healthcare-focused real estate broker, construction should begin next year on what is being called the […]

    Source: Xconomy New York
  • The Look: New York City Parks in the Summer: Romance, Games and a Performance for a Dying Tree
    By DANIEL ARNOLD, JOANNA NIKAS and EVE LYONS - Saturday Sep 2, 2017

    Daniel Arnold spent the last two months photographing parks in all five boroughs. The experience showed him “a very different pulse of the city.”

    Source: NYT > Home Page
  • Syntimmune Snares $50M to Test Autoimmune Drug in Two Rare Diseases
    By Frank Vinluan - Wednesday Jun 21, 2017

    Although antibodies play a key role in neutralizing invading bacteria and viruses, sometimes these protective proteins can turn against the body’s own tissues, sparking an autoimmune disorder. Syntimmune’s leaders believe their company has found a way to block the immune system’s attack on the body. And now the biotech has $50 million to advance its […]

    Source: Xconomy New York
  • “It’s Shame On Us If We Blow It”: Highlights From NY Seizes the Momentum
    By Ben Fidler - Wednesday Jun 7, 2017

    Mike Foley, a drug industry veteran and director of the Tri-Institutional Therapeutics Discovery Institute, has a pointed message for the New York life sciences industry: Don’t waste the moment. Changing the course of New York biotech has been a saga that dates back to the 1990s, and as Xconomy has detailed, progress has been made […]

    Source: Xconomy New York
  • Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
    By Ben Fidler - Tuesday Sep 12, 2017

    Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]

    Source: Xconomy New York